B7-H3-targeted 212Pb radioimmunotherapy of ovarian cancer in preclinical models
Novel therapies that effectively kill both differentiated cancer cells and cancer initiating cells (CICs), which are implicated in causing chemotherapy-resistance and disease recurrence, are needed to reduce the morbidity and mortality of ovarian cancer. These studies used monoclonal antibody (mAb) 376.96, which recognizes a B7-H3 epitope expressed on ovarian cancer cells and CICs, as a carrier molecule for targeted α-particle radioimmunotherapy (RIT) in preclinical models of human ovarian cancer. (Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - January 9, 2017 Category: Nuclear Medicine Authors: Benjamin B. Kasten, Rebecca C. Arend, Ashwini A. Katre, Harrison Kim, Jinda Fan, Soldano Ferrone, Kurt R. Zinn, Donald J. Buchsbaum Source Type: research
Cannabinoid receptor type 2 (CB2) as one of the candidate genes in human carotid plaque imaging: Evalu1ation of the novel radiotracer [11C]RS-016 targeting CB2 in atherosclerosis
Endarterectomized human atherosclerotic plaques are a valuable basis for gene expression studies to disclose novel imaging biomarkers and therapeutic targets, such as the cannabinoid receptor type 2 (CB2). In this work, CB2 is expressed on activated immune cells, which are abundant in inflamed plaques. We evaluated the CB2-specific radiotracer [11C]RS-016 for imaging vascular inflammation in human and mouse atherosclerotic lesions. (Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - January 7, 2017 Category: Nuclear Medicine Authors: Romana Meletta, Roger Slavik, Linjing Mu, Zoran Rancic, Nicole Borel, Roger Schibli, Simon M. Ametamey, Stefanie D. Kr ämer, Adrienne Müller Herde Source Type: research
Cannabinoid receptor type 2 (CB2) as one of the candidate genes in human carotid plaque imaging and evaluation of the novel radiotracer [11C]RS-016 targeting CB2 in atherosclerosis
Endarterectomized human atherosclerotic plaques are a valuable basis for gene expression studies to disclose novel imaging biomarkers and therapeutic targets, such as the cannabinoid receptor type 2 (CB2). In this work, CB2 is expressed on activated immune cells, which are abundant in inflamed plaques. We evaluated the CB2-specific radiotracer [11C]RS-016 for imaging vascular inflammation in human and mouse atherosclerotic lesions. (Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - January 7, 2017 Category: Nuclear Medicine Authors: Romana Meletta, Roger Slavik, Linjing Mu, Zoran Rancic, Nicole Borel, Roger Schibli, Simon M. Ametamey, Stefanie D. Kr ämer, Adrienne Müller Herde Source Type: research
A multi species evaluation of the radiation dosimetry of [11C]erlotinib, the radiolabeled analog of a clinically utilized tyrosine kinase inhibitor
The objectives of this study were to (1) establish a human dosimetry profile of [11C]erlotinib and (2) assess the consistency of calculated equivalent dose across species using the same dosimetry model. (Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - January 2, 2017 Category: Nuclear Medicine Authors: J. Ryan Petrulli, S øren B. Hansen, Galith Abourbeh, Maqsood Yaqub, Idris Bahce, Daniel Holden, Yiyun Huang, Nabeel B. Nabulsi, Joseph N. Contessa, Eyal Mishani, Adriaan A. Lammertsma, Evan D. Morris Source Type: research
Monoanionic 99mTc-tricarbonyl-aminopolycarboxylate complexes with uncharged pendant groups: Radiosynthesis and evaluation as potential renal tubular tracers
99mTc(CO)3-nitrilotriacetic acid, 99mTc(CO)3(NTA), is a new renal tubular agent with pharmacokinetic properties comparable to those of 131I-OIH but the clearance of 99mTc(CO)3(NTA) and 131I-OIH is still less than the clearance of PAH, the gold standard for the measurement of effective renal plasma flow. At physiological pH, dianionic 99mTc(CO)3(NTA) has a mononegative inner metal-coordination sphere and a mononegative uncoordinated carboxyl group. To evaluate alternate synthetic approaches, we assessed the importance of an uncoordinated carboxyl group, long considered essential for tubular transport, by evaluating the phar...
Source: Nuclear Medicine and Biology - December 26, 2016 Category: Nuclear Medicine Authors: Malgorzata Lipowska, Jeffrey Klenc, Nashwa Jarkas, Luigi G. Marzilli, Andrew T. Taylor Source Type: research
99mTc renal tracers with uncharged pendant groups
99mTc(CO)3-nitrilotriacetic acid, 99mTc(CO)3(NTA), is a new renal tubular agent with pharmacokinetic properties comparable to those of 131I –OIH but the clearance of 99mTc(CO)3(NTA) and 131I–OIH are still less than the clearance of PAH, the gold standard for the measurement of effective renal plasma flow. At physiological pH, dianionic 99mTc(CO)3(NTA) has a mononegative inner metal-coordination sphere and a mononegative uncoordinate d carboxyl group. To evaluated alternate synthetic approaches, we assessed the importance of an uncoordinated carboxyl group, long considered essential for tubular transport, by evaluating ...
Source: Nuclear Medicine and Biology - December 26, 2016 Category: Nuclear Medicine Authors: Malgorzata Lipowska, Jeffrey Klenc, Nashwa Jarkas, Luigi G. Marzilli, Andrew T. Taylor Source Type: research
Investigation of 123I production using electron accelerator
The possibility of 123I isotope production with the help of the high-intensity bremsstrahlung photons produced by the electron beam of the LUE50 linear electron accelerator at the A.I.Alikhanyan National Science Laboratory (Yerevan Physics Institute - YerPhI) is considered. The production method has been established and shown to be successful. The 124Xe( γ,n)123Xe→123I nuclear reaction has been investigated and the cross-section was calculated by nuclear codes TALYS 1.6 and EMPIRE 3.2. The optimum parameter of the thickness of the target was determined by GEANT4 code. (Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - December 21, 2016 Category: Nuclear Medicine Authors: Albert Avetisyan, Robert Avagyan, Ruben Dallakyan, Gohar Avdalyan, Nikolay Dobrovolsky, Vasak Gavalyan, Ivetta Kerobyan, Gevorg Harutyunyan Source Type: research
Quantitation of rat cerebral blood flow using 99mTc-HMPAO
Technetium-99m-hexamethylpropyleneamine oxime (99mTc-HMPAO) is potentially useful for the assessment of cerebral blood flow (CBF) in small animals. In this paper, a procedure for quantitation of rat CBF using 99mTc-HMPAO was determined. (Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - December 21, 2016 Category: Nuclear Medicine Authors: Chie Suzuki, Shintaro Kimura, Mutsumi Kosugi, Yasuhiro Magata Source Type: research
Radiopharmaceutical Chemistry of Targeted Radiotherapeutics, Part 4: Strategies for 211At Labeling at High Activities and Radiation Doses of 211At α-Particles
Alpha particles are radiation of high energy and short range, properties that can lead to radiolysis-mediated complications in labeling chemistry at the high radioactivity levels required for clinical application. In previous papers in this series, we have shown that radiation dose has a profound effect on the astatine species that are present in the labeling reaction and their suitability for the synthesis of N-succinimidyl 3-[211At]astatobenzoate. The purpose of this study was to evaluate the effects of adding N-chlorosuccinimide (NCS) to the methanol solution used for initial isolation of 211At after distillation, a pro...
Source: Nuclear Medicine and Biology - December 11, 2016 Category: Nuclear Medicine Authors: Oscar R. Pozzi, Michael R. Zalutsky Source Type: research
Development of [11C]/[3H]THK-5351 – A Potential Novel Carbon-11 Tau Imaging PET Radioligand
Due to the rise in the number of patients with dementia the imperative for finding new diagnostic and treatment options becomes ever more pressing. While significant progress has been made in PET imaging of A β aggregates both in vitro and in vivo, options for imaging tau protein aggregates selectively are still limited. Based on the work previously published by researchers from the Tohoku University, Japan, that resulted in the development of [18F]THK-5351, we have undertaken an effort to develop a car bon-11 version of the identical structure - [11C]THK-5351. (Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - December 8, 2016 Category: Nuclear Medicine Authors: Vladimir Stepanov, Marie Svedberg, Zhisheng Jia, Raisa Krasikova, Laetitia Lemoine, Nobujuki Okamura, Shozo Furumoto, Nicholas Mitsios, Jan Mulder, Bengt L ångström, Agneta Nordberg, Christer Halldin Source Type: research
Intraarticular and intravenous administration of 99MTc-HMPAO-labeled human mesenchymal stem cells (99MTC-AH-MSCS). In vivo imaging and biodistribution
Therapeutic application of intravenous administered (IV) human bone marrow-derived mesenchymal stem cells (ahMSCs) appears to have as main drawback the massive retention of cells in the lung parenchyma, questioning the suitability of this via of administration. Intraarticular administration (IAR) could be considered as an alternative route for therapy in degenerative and traumatic joint lesions. Our work is outlined as a comparative study of biodistribution of 99mTc-ahMSCs after IV and IAR administration, via scintigraphic study in an animal model. (Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - December 8, 2016 Category: Nuclear Medicine Authors: Luis Meseguer-Olmo, Antonio Jes ús Montellano, Teresa Martínez, Carlos M. Martínez, Beatriz Revilla-Nuin, Marta Roldán, Cristina Fuente Mora, Maria Dolores López-Lucas, Teodomiro Fuente Source Type: research
Synthesis and evaluation of a 99mTc tricarbonyl-labeled somatostatin receptor-targeting antagonist peptide for imaging of neuroendocrine tumors
A somatostatin receptor (SSTR)-targeting antagonist peptide (sst2-ANT) was radiolabeled with 99mTc tricarbonyl via a tridentate [N,S,N]-type ligand (L) to develop a radiodiagnostic agent, 99mTcL-sst2-ANT, for imaging of SSTR-expressing neuroendocrine tumors. (Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - December 8, 2016 Category: Nuclear Medicine Authors: Lauren Radford, Fabio Gallazzi, Lisa Watkinson, Terry Carmack, Ashley Berendzen, Michael R. Lewis, Silvia S. Jurisson, Dionysia Papagiannopoulou, Heather M. Hennkens Source Type: research
PET Studies in non-Human Primates: Choosing Drug Doses
The techniques of molecular imaging, and in particular Positron Emission Tomography (PET), have provided scientists with exciting possibilities of non-invasive studies of the biochemistry of the living brain. Through the use of radiolabeled tracers and pharmacological interventions, the interconnections of neurochemical systems can be examined as a means to better understand the brain and the effects of drugs on its function. (Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - December 8, 2016 Category: Nuclear Medicine Authors: Michael R. Kilbourn Tags: Editorial Source Type: research
(1 →3)-β-D-glucan aptamers labeled with technetium-99m: Biodistribution and imaging in experimental models of bacterial and fungal infection
Acid nucleic aptamers are RNA or DNA oligonucleotides capable of binding to a target molecule with high affinity and selectivity. These molecules are promising tools in nuclear medicine. Many aptamers have been used as targeting molecule of radiopharmaceuticals in preclinical studies. (1 →3)-β-D-glucans are the main structural cell wall components of fungi and some bacteria. In the present study two radiolabeled (1→3)-β-D-glucan aptamers (seq6 and seq30) were evaluated to identity infectious foci caused by fungal or bacterial cells. (Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - November 28, 2016 Category: Nuclear Medicine Authors: Camila Maria de Sousa Lacerda, I êda Mendes Ferreira, Sara Roberta dos Santos, André Luís Branco de Barros, Simone Odília Fernandes, Valbert Nascimento Cardoso, Antero Silva Ribeiro de Andrade Source Type: research
Nanozeolite bioconjugates labeled with 223Ra for targeted alpha therapy
Alpha particle emitting isotopes are of considerable interest for radionuclide therapy because of their high cytotoxicity and short path length. Among the many α emitters, 223Ra exhibits very attractive nuclear properties for application in radionuclide therapy. The decay of this radioisotope and its daughters is accompanied by the emission of four α-particles, releasing 27.9MeV of cumulative energy. Unfortunately the lack of an appropriate bifunctional ligand for radium has so far been a main obstacle for the application of 223Ra in receptor targeted therapy. (Source: Nuclear Medicine and Biology)
Source: Nuclear Medicine and Biology - November 16, 2016 Category: Nuclear Medicine Authors: Agata Piotrowska, Sylwia M ęczyńska-Wielgosz, Agnieszka Majkowska-Pilip, Przemysław Koźmiński, Grzegorz Wójciuk, Edyta Cędrowska, Frank Bruchertseifer, Alfred Morgenstern, Marcin Kruszewski, Aleksander Bilewicz Source Type: research
